- Details
- Description
-
Packaging Size1Bottle/Box
-
Strength40mg/1ml
-
CompositonToripalimab (特瑞普利单抗)
-
TreatmentNasopharyngeal Carcinoma (NPC)
-
FormInjection
-
BrandLoqtorzi (拓益)
-
Quantity Unit240mg*6ml/Bottle/Box
-
ManufacturerJunshi Biosciences,China
About Toripalimab
Loqtorzi (toripalimab-tpzi) sold under the brand name 拓益 in china, is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.
Approved
On October 27, 2023
The FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).
FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
September 24, 2024
Shanghai -- On September 24, 2024, Beijing time, Junshi Biosciences (1877.HK, 688180.SH) announced that the company's independently developed anti-PD-1 monoclonal antibody drug Toripalimab (European trade name: LOQTORZI®) has recently been approved by the European Commission (EC) for the treatment of two indications:
- Toripalimab combined with cisplatin and gemcitabine is used for the first-line treatment of adult patients with recurrent, inoperable or radiotherapy-intolerant, or metastatic nasopharyngeal carcinoma (NPC);
- Toripalimab combined with cisplatin and paclitaxel is used for the first-line treatment of adult patients with unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
